Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata - 07/08/11
Reprint requests: Madeleine Duvic, MD, Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Box 434, 1515 Holcombe Blvd, Houston, TX 77030-4095.Abstract |
Background |
Alopecia areata, hair loss caused by perifollicular T-cell infiltrates, is refractory to therapy. Bexarotene, a retinoid X receptor is a selective retinoid, induces T-cell apoptosis.
Objective |
We sought to determine the safety, including the dose-limiting toxicities with adverse events, and efficacy, ie, response rate, of bexarotene in alopecia areata.
Methods |
We conducted a phase I/II randomized, half-head trial of 1% bexarotene gel applied twice daily for 6 months.
Results |
In all, 42 patients (11 male and 31 female) with alopecia totalis (n = 3), alopecia universalis (n = 5), or alopecia areata (n = 34) applied 1% bexarotene gel for 24 weeks. Five of 42 (12%) had 50% or more partial hair regrowth on the treated side, and 6 of 42 (14%) on both sides including 3 complete responders. In all, 31 patients had mild irritation; 4 had grade-3 irritation.
Limitations |
This design cannot differentiate between drug-induced and spontaneous regrowth.
Conclusion |
Topical bexarotene 1% application is well tolerated and possibly effective. A randomized placebo-controlled trial should be conducted.
El texto completo de este artículo está disponible en PDF.Key words : alopecia areata, alopecia totalis, alopecia universalis, bexarotene gel
Abbreviations used : AA, AT, AU, PUVA, SADBE, UV
Esquema
| This single-center trial was supported in part by a clinical grant from Ligand Pharmaceuticals, by the National Cancer Institute (NCI), M. D. Anderson Cancer Center (MDACC) Core Grant CA16672-22, NCI (R21-CA74117), National Institute of Arthritis, Musculoskeletal and Skin Diseases, (NIAMS) K24 CA 86815. |
|
| Conflicts of interest: None declared. |
|
| Presented in part at the 63rd American Academy of Dermatology Meeting in New Orleans, LA, February 18-22, 2005. |
Vol 61 - N° 4
P. 592.e1-592.e9 - octobre 2009 Regresar al número
Artículo precedente
- History of atopy or autoimmunity increases risk of alopecia areata
- Nazila Barahmani, Matthew B. Schabath, Madeleine Duvic, National Alopecia Areata Registry
- How good are skin cancer clinics at melanoma detection? Number needed to treat variability across a national clinic group in Australia
- Craig Hansen, David Wilkinson, Mary Hansen, Giuseppe Argenziano
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?